ARTICLE | Clinical News
TAK-390MR: Phase III data
May 26, 2008 7:00 AM UTC
In a double-blind, international Phase III trial in 2,046 patients with Grade A-D erosive esophagitis, 60 and 90 mg of TAK-390MR met the primary endpoint of non-inferior healing rates vs. 30 mg of lan...